SCHEDULE OF ACCRUED EXPENSES (Details) - USD ($) |
Mar. 31, 2021 |
Dec. 31, 2020 |
|---|---|---|
| Payables and Accruals [Abstract] | ||
| Accrued clinical operations and trials costs | $ 11,956,892 | $ 14,132,842 |
| Accrued product development costs | 764,211 | 2,189,047 |
| Accrued compensation | 3,746,283 | 4,222,594 |
| Accrued other | 1,275,088 | 1,460,949 |
| Total | $ 17,742,474 | $ 22,005,432 |
| X | ||||||||||
- Definition Accrued clinical operations and trials costs current. No definition available.
|
| X | ||||||||||
- Definition Accrued product development costs current. No definition available.
|
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|